Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline...
Results across all efficacy endpoints consistently favored vafidemstat over placebo. Global Statistical Test (GST p-values) confirms consistent trend across efficacy endpoints.
-
NewHow does the quality of controls affect the results in a research project?
To drive research efforts, it is key to choose world-class controls, and to understand them not as mere tools, but as indispensable assets that guarantee the highest quality standards, saving time and
-
NewORYZON to provide corporate progress updates at several events in January
He highlights his participation in the 7º Sachs Annual Neuroscience Innovation Forum, 13º Annual LifeSci Advisors Corporate Access Event, Biotech Showcase-2024, 42º Annual J.P. Morgan Healthcare
-
NewImpact of US Inflation Reduction Act on EU Biotech Companies
In 2022, the Inflation Reduction Art (IRA) became US law with the aim to reduce drug costs.
-
NewIntegra Therapeutics announces key additions to its Scientific Advisory Board
The SAB will provide strategic guidance on the company's research and development efforts and strategy, particularly focused on the FiCAT gene writing platform that improves the development of gene
-
CompanyTHYTECH S.L.
-
NewRocío Arroyo, CEO of Amadix, new president of AseBio
In the General Assembly of AseBio, new vice-presidents have also been elected: Carlos Buesa, CEO of Oryzon (First Vice-presidency); Cristina Nadal, Policy Executive Director of MSD Spain (Second Vice
-
Press releaseRocío Arroyo, CEO of Amadix, new president of AseBio
In the General Assembly of AseBio, new vice-presidents have also been elected: Carlos Buesa, CEO of Oryzon (First Vice-presidency); Cristina Nadal, Policy Executive Director of MSD Spain (Second Vice
-
NewVIVEbiotech achieves significant business growth in 2023 with increases in demand for its ...
Recent company sales grow by 70%, reflecting expanded capabilities and industry recognition of VIVEbiotech’s expertise in manufacturing lentiviruses, now used in in 70% of global ex-vivo CGT clinical
-
-
EventBio Equity Europe
-
-
EventLSX WORLD CONGRESS
-
-
EventSwiss Biotech Day
-
NewInnovation in mental health
Innovation has enabled breakthroughs such as recent drugs for Alzheimer's disease, the use of devices that stimulate brain function for the treatment of certain pathologies or Virtual Reality for post
-
NewBiotechnology is behind more than 40% of the active ingredients in medications included in...
Over the last 40 years, biotechnology has shaped the landscape of medicine, as evidenced by the fact that 69% of drugs in development are a result of biotechnological advancements.
-
Press releaseBiotechnology is behind more than 40% of the active ingredients in medications included in...
The list, comprised of 268 drugs, is an important tool to support the EU's efforts to ensure the security of the supply chain and prevent shortages of critical medications. Over the last 40 years
-
New#NewAseBioMember | "AseBio is a key reference entity in the Spanish and European biotechno...
Meet BeCytes Biotechnologies, our new member. We talked with Estephan Arredondo Córdova, Technical Director
-
New#NewAllyAseBio | "AseBio represents the meeting place for all the companies in the biotech...
Meet JORI & ARMENGOL, our new ally. We talked to María Sanjuanbenito, ejecutiva de Cuentas.
-
AllyJORI & ARMENGOL CORREDURÍA DE SEGUROS Y REASEGUROS S.L.
JORI is a risk consultancy and insurance brokerage specialized in business insurance, with special expertise in Lifescience. We are partners in the I4CT (Insurance For Clinical Trials) platform